One of the most frequently researched parameters for MK-2866 (Ostarine) is its elimination half-life — the time required for plasma concentration to decrease by 50% following administration. This parameter has direct relevance to dosing interval design in clinical research, in-vitro assay timing, and anti-doping analytical method development. This post consolidates published pharmacokinetic data on MK-2866’s half-life across species and experimental conditions.

This is a research information resource. MK-2866 is not approved by the Therapeutic Goods Administration (TGA) for any human use.

Why Half-Life Matters in SARM Research

The elimination half-life (t½) determines how long a compound remains at experimentally relevant concentrations in a biological system. A drug reaches steady-state plasma concentration after approximately 4–5 half-lives of repeated dosing, and is substantially eliminated after 5 half-lives following the last dose.

For in-vitro researchers, half-life data informs media change intervals in long-term cell culture experiments, compound restocking frequency in multi-day assays, interpretation of dose-response relationships in time-course studies, and comparison of MK-2866 to other AR agonists in experimental design.

Pre-Clinical Half-Life Data: Rodent Models

The foundational pharmacokinetic characterisation of MK-2866 in rodents was conducted by GTx researchers. Key published parameters from intravenous (IV) administration in rats (10 mg/kg):

• Terminal half-life (t½β): approximately 6.0 hours
• Initial half-life (t½α): approximately 0.5–1.0 hours (distribution phase)
• Plasma concentration profile: biphasic decline consistent with two-compartment pharmacokinetic model

The 6-hour terminal half-life for MK-2866 was notably longer than comparator compounds in GTx’s SARM series, which exhibited half-lives of 2.6–4.0 hours under identical conditions. This extended half-life is attributed to structural differences affecting hepatic clearance rates and plasma protein binding affinity — properties that also translate to a longer human half-life relative to most structurally distinct SARMs.

Human Pharmacokinetic Data: Clinical Phase I Findings

MK-2866 progressed to Phase I and Phase II clinical trials under GTx Inc., providing rare human PK data for a SARM candidate.

Single-Dose Parameters (Human, Oral)

• Terminal elimination half-life: 24–36 hours
• Time to maximum plasma concentration (Tmax): approximately 1–2 hours post-oral dose
• Dose proportionality: Cmax and AUC increase proportionally across the studied dose range (1–100 mg) — linear pharmacokinetics confirmed
• Oral bioavailability: estimated >80% based on PK modelling

The substantially longer human half-life (24–36 hours) compared to the rat half-life (6 hours) reflects species differences in cytochrome P450 activity, plasma protein binding characteristics, and renal clearance kinetics. This species scaling factor is important for researchers translating pre-clinical dosing data to human exposure modelling.

Multiple-Dose Pharmacokinetics

Consistent with its single-dose half-life, steady-state plasma concentrations in human Phase I studies were reached within approximately 5–7 days of daily dosing. Accumulation ratios were predictable from single-dose PK, with no evidence of enzyme induction or inhibition causing non-linear accumulation. This linear, predictable PK behaviour is an advantage for research protocols requiring stable AR receptor occupancy over extended periods.

Metabolite Profiles and Detection Windows

MK-2866 undergoes hepatic biotransformation via CYP3A4-mediated aromatic hydroxylation (producing M1, which retains partial AR binding activity) and subsequent glucuronide conjugation. These water-soluble conjugates are the dominant species in urine and the primary targets for anti-doping urinalysis.

Published anti-doping research indicates urinary detection windows of:

• Parent compound: 2–7 days post-dose depending on dose level and analytical sensitivity
• Phase II metabolites (glucuronides): up to 9–19 days post-dose in some subjects

The extended metabolite detection window relative to parent compound half-life is relevant for researchers developing analytical methods and for sports drug testing programme design.

Plasma Protein Binding and Free Fraction

MK-2866 binds plasma proteins — primarily albumin and SHBG — with protein binding reported at 86–99% in human plasma. For in-vitro researchers using serum-containing media, effective free concentrations will be approximately 10–50-fold lower than nominal concentrations depending on serum percentage. This should be accounted for when extrapolating in-vitro EC50 values and when comparing results across different cell culture conditions.

Stability Data for Research Use

• DMSO stock solution (−20°C, sealed, protected from light): stable ≥12 months
• Human plasma (−20°C): stable through ≥3 freeze-thaw cycles; ≥12 months at −80°C
• Whole blood (room temperature): stable approximately 2 hours; centrifuge promptly
• Aqueous solution: limited stability; prepare fresh from DMSO stock for each experiment

Half-Life Comparison: MK-2866 vs. Other Research SARMs

Compound	Rat t½ (IV)	Human t½ (oral, est.)
MK-2866 (Ostarine)	~6 hours	24–36 hours
LGD-4033 (Ligandrol)	~5 hours	24–36 hours
RAD-140 (Testolone)	~60 hours	~60 hours (est.)
S-23	~11.9 hours	Not established

Summary: Key Half-Life Parameters for MK-2866

• Rat IV (10 mg/kg): ~6 hours terminal half-life
• Human oral (Phase I): 24–36 hours terminal half-life
• Steady-state (daily dosing): reached within ~5–7 days
• Urinary detection window: up to ~19 days for phase II metabolites
• DMSO stock stability (−20°C): ≥12 months

MK-2866’s extended and well-characterised half-life, combined with linear pharmacokinetics and high oral bioavailability, makes it a practical reference compound for research protocols requiring predictable AR activation over extended timeframes.

Ostarine Australia supplies pharmaceutical-grade MK-2866 for in-vitro laboratory and research use only. View current batch Certificates of Analysis → | Read: MK-2866 Mechanism of Action →